HCM and New Pharmacological Agents

Presenters: Ferhaan Ahmad, MD, PhD, FRCPC, FAHA, FACC; Sara Saberi, MD, MS; Anjali Tiku Owens, MD; Pastor Kent Sperry, MDiv

Summary: Making the correct of hypertrophic cardiomyopathy (HCM) is critical in being able to initiate early surveillance and therapy to improve patient outcomes. In this podcast focusing on pharmacologic treatment options, learn more about completed and ongoing myosin inhibitor clinical trials.

Ferhaan Ahmad MD PhD
Ferhaan Ahmad, MD, PhD
Associate Professor of Internal Medicine, Radiology, and Molecular Physiology and Biophysics
Director, Cardiovascular Genetics Program
Director, Cardiovascular Disease Fellowship Program
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine
Sara Saberi MD
Sara Saberi, MD, MS
Assistant Professor
Inherited Cardiomyopathy Program
Frankel Cardiovascular Center
University of Michigan Hospital, Michigan Medicine
Anjali Owens MD
Anjali Tiku Owens, MD
Assistant Professor of Medicine
University of Pennsylvania
Kent Sperry MD
Kent Sperry, MDiv
Patient Representative